Ando Y - Search Results

1

Extension of the Calvert formula to patients with severe renal insufficiency.

Oguri T, Shimokata T, Ito I, Yasuda Y, Sassa N, Nishiyama M, Hamada A, Hasegawa Y, Ando Y. Oguri T, et al. Among authors: ando y. Cancer Chemother Pharmacol. 2015 Jul;76(1):53-9. doi: 10.1007/s00280-015-2769-9. Epub 2015 May 10. Cancer Chemother Pharmacol. 2015. PMID: 25957958 Clinical Trial.

2

Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y. Ando Y, et al. Ther Drug Monit. 2002 Feb;24(1):111-6. doi: 10.1097/00007691-200202000-00018. Ther Drug Monit. 2002. PMID: 11805731

3

Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.

Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, Hasegawa Y. Ando M, et al. Among authors: ando y. Jpn J Cancer Res. 2002 May;93(5):591-7. doi: 10.1111/j.1349-7006.2002.tb01295.x. Jpn J Cancer Res. 2002. PMID: 12036456 Free PMC article.

4

Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.

Ando M, Saka H, Ando Y, Minami H, Kuzuya T, Yamamoto M, Watanabe A, Sakai S, Shimokata K, Hasegawa Y. Ando M, et al. Among authors: ando y. Cancer Chemother Pharmacol. 2005 Jun;55(6):552-8. doi: 10.1007/s00280-004-0921-z. Epub 2005 Mar 15. Cancer Chemother Pharmacol. 2005. PMID: 15856233 Clinical Trial.

5

Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.

Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K, Imaizumi K, Shimokata K, Hasegawa Y. Kitagawa C, et al. Among authors: ando y, ando m. Pharmacogenet Genomics. 2005 Jan;15(1):35-41. doi: 10.1097/01213011-200501000-00006. Pharmacogenet Genomics. 2005. PMID: 15864124

6

Clinical pharmacogenetics of irinotecan (CPT-11).

Ando Y, Hasegawa Y. Ando Y, et al. Drug Metab Rev. 2005;37(3):565-74. doi: 10.1080/03602530500316254. Drug Metab Rev. 2005. PMID: 16257834 Review.

7

Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.

Ando M, Hasegawa Y, Ando Y. Ando M, et al. Among authors: ando y. Invest New Drugs. 2005 Dec;23(6):539-45. doi: 10.1007/s10637-005-4022-6. Invest New Drugs. 2005. PMID: 16267624

8

Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.

Hasegawa Y, Ando Y, Shimokata K. Hasegawa Y, et al. Among authors: ando y. Expert Rev Mol Diagn. 2006 Jul;6(4):527-33. doi: 10.1586/14737159.6.4.527. Expert Rev Mol Diagn. 2006. PMID: 16824027 Review.

9

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.

Hasegawa Y, Ando Y, Ando M, Hashimoto N, Imaizumi K, Shimokata K. Hasegawa Y, et al. Among authors: ando y, ando m. Ann N Y Acad Sci. 2006 Nov;1086:223-32. doi: 10.1196/annals.1377.020. Ann N Y Acad Sci. 2006. PMID: 17185519 Review.

10

UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.

Ando Y, Fujita K, Sasaki Y, Hasegawa Y. Ando Y, et al. Curr Opin Mol Ther. 2007 Jun;9(3):258-62. Curr Opin Mol Ther. 2007. PMID: 17608024 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,816 results

Search Page

Filters